DEA Rules on Doctor's Fate in Routine Order
Published Date: 12/22/2025
Notice
Summary
Dr. David Halvorson from Alabama lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of October 31, 2025. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Halvorson
The DEA revoked David Halvorson, M.D.'s Certificate of Registration No. BH3453278 and denied any pending applications to renew, modify, or obtain additional registration in Alabama. The Order is effective January 21, 2026; the record also shows his Alabama medical license was revoked on or about June 6, 2025 and his DEA registration expired on October 31, 2025.
DEA Policy: State Authority Required
Under 21 U.S.C. 824(a)(3) and long-standing DEA precedent cited in this Order, the DEA will revoke a practitioner's federal controlled-substances registration if the practitioner no longer has state authority to dispense controlled substances (for example, after a state license suspension or revocation). The Order reiterates that possession of state authority to dispense controlled substances is a fundamental condition for obtaining and maintaining a DEA practitioner registration.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2025-23544, Notice of Inventory Completion: Florida Department of State, Tallahassee, FL
The Florida Department of State has finished checking some Native American human remains and found they belong to the Pueblo of Jemez tribe. Starting January 21, 2026, these remains can be returned to the tribe. This is part of a respectful effort to give back important cultural items and remains to Native communities.
Next: 2025-23546, Submission for Office of Management and Budget Review; Proposed Information Collection Activity; Office of Community Services Community Economic Development Performance Progress Report
The Office of Community Services is updating how community economic development grant recipients report their progress. New awardees will now submit shorter reports every quarter, while others stick to twice a year. This change helps keep projects on track and improves how the government supports and tracks job creation and spending, with comments due by January 21, 2026.